These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 967232)

  • 41. Palatability-induced drinking after administration of morphine, naltrexone and diazepam in the non-deprived rat.
    Cooper SJ
    Subst Alcohol Actions Misuse; 1982; 3(5):259-66. PubMed ID: 7167863
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical evaluation of a naltrexone sustained-release preparation.
    Chiang CN; Hollister LE; Gillespie HK; Foltz RL
    Drug Alcohol Depend; 1985 Sep; 16(1):1-8. PubMed ID: 4064907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone.
    Porter SJ; Somogyi AA; White JM
    Addict Biol; 2002 Apr; 7(2):219-25. PubMed ID: 12006217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Testing of drug delivery systems for use in the treatment of narcotic addiction.
    Reuning RH; Malspeis L; Frank S; Notari RE
    Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):43-5. PubMed ID: 823438
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An improved long-acting delivery system for narcotic antagonists.
    Misra AL; Pontani RB
    J Pharm Pharmacol; 1978 May; 30(5):325-6. PubMed ID: 26754
    [No Abstract]   [Full Text] [Related]  

  • 46. Naltrexone improves survival rate and cardiovascular function in canine hemorrhagic shock.
    Gurll NJ; Reynolds DG; Vargish T; Lechner R
    J Pharmacol Exp Ther; 1982 Mar; 220(3):625-8. PubMed ID: 6278127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kinetics of a naltrexone sustained-release preparation.
    Chiang CN; Hollister LE; Kishimoto A; Barnett G
    Clin Pharmacol Ther; 1984 Nov; 36(5):704-8. PubMed ID: 6488691
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration.
    Kogan MJ; Verebey K; Mule SJ
    Res Commun Chem Pathol Pharmacol; 1977 Sep; 18(1):29-34. PubMed ID: 905632
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential effects of morphine and naltrexone on the in vitro LH secretion from male and female carp pituitary gland.
    Sokolowska-Mikolajczyk M; Socha M; Mikolajczyk T; Chyb J; Szymacha J; Epler P
    Comp Biochem Physiol C Toxicol Pharmacol; 2005 Aug; 141(4):325-31. PubMed ID: 16198154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Historical perspective on the chemistry and development of naltrexone.
    Archer S
    NIDA Res Monogr; 1981; 28():3-10. PubMed ID: 6791011
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Naltrexone metabolism and sustained release following administration of an insoluble complex to rhesus monkeys and guinea-pigs.
    Macgregor TR; Drum MA; Harrigan SE; Wiley JN; Reuning RH
    J Pharm Pharmacol; 1983 Jan; 35(1):38-42. PubMed ID: 6131962
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Electrochemical chromatographic determinations of morphine antagonists in biological fluids, with applications.
    Derendorf H; El-Din A; El-Koussi A; Garrett ER
    J Pharm Sci; 1984 May; 73(5):621-4. PubMed ID: 6737235
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of injectable microcapsules for use in the treatment of narcotic addiction.
    Thies C
    Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):19-20. PubMed ID: 967230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stereochemical studies on medicinal agents. 23. Synthesis and biological evaluation of 6-amino derivatives of naloxone and naltrexone.
    Jiang JB; Hanson RN; Portoghese PS; Takemori AE
    J Med Chem; 1977 Aug; 20(8):1100-2. PubMed ID: 894682
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention by naltrexone of tolerance to the rate-decreasing effects of morphine on schedule-controlled responding in the pigeon.
    Smith JB
    Psychopharmacology (Berl); 1979 May; 63(1):49-54. PubMed ID: 112621
    [No Abstract]   [Full Text] [Related]  

  • 57. Naltrexone pharmacology, pharmacokinetics, and metabolism: current status.
    Verebey K; Mulé SJ
    Am J Drug Alcohol Abuse; 1975; 2(3-4):357-63. PubMed ID: 1227297
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacokinetic quantitation of naltrexone controlled release from a copolymer delivery system.
    Reuning RH; Liao SH; Staubus AE; Ashcraft SB; Downs DA; Harrigan SE; Wiley JN; Wise DL
    J Pharmacokinet Biopharm; 1983 Aug; 11(4):369-87. PubMed ID: 6422028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of yohimbine and naltrexone in counteraction of the morphine Straub tail and the amphetamine-potentiated morphine Straub tail in mice.
    Blumberg H; Slovak DM
    Life Sci; 1982 Jun; 30(24):2115-21. PubMed ID: 7109840
    [No Abstract]   [Full Text] [Related]  

  • 60. Inhibition of drug metabolism by chronically administered naltrexone.
    Lehman TM; Pyati P; Peterson GR
    Life Sci; 1979 Oct; 25(18):1591-600. PubMed ID: 522615
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.